Iradimed Corp. (NASDAQ: IRMD) reported Q4 EPS of $0.33, $0.12 better than the analyst estimate of $0.21. Revenue for the quarter came in at $11.9 million versus the consensus estimate of $11.63 million.

GUIDANCE:

Iradimed Corp. sees Q1 2022 EPS of $0.20-$0.21. Iradimed Corp. sees Q1 2022 revenue of $12.1-12.1 million, versus the consensus of $11.07 million.

Iradimed Corp. sees FY2022 EPS of $0.91-$1.01, versus the consensus of $0.83. Iradimed Corp. sees FY2022 revenue of $51.4-52.2 million, versus the consensus of $45.62 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.